Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Press Releases

Press Releases

  • Apr 10, 2019
    Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
    Topline data readout from Huntington’s disease clinical trials now expected by year end 2019 CAMBRIDGE, Mass. , April 10, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling
  • Mar 25, 2019
    Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference
    CAMBRIDGE, Mass. , March 25, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlighting new data and
  • Mar 06, 2019
    Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference
    CAMBRIDGE, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno , MD, MBA, President and Chief Executive
  • Jan 24, 2019
    Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
    CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today the pricing of its previously announced underwritten
  • Jan 23, 2019
    Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares
    CAMBRIDGE, Mass. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, announced today that it has commenced an underwritten public offering of




  • Events and Presentation